SEC Form 20-F filed by Virax Biolabs Group Limited
$VRAX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/31/2025 | $3.00 | Buy | H.C. Wainwright |
Fiscal 2026 Annual Report, filed July 2, 2026, reflects cash of $6.4 million, total assets of $8.3 million and shareholders' equity attributable to ordinary shareholders of $7.3 millionFosun Diagnostics agreement, announced July 9, 2026, supports commercial execution for ImmuneSelect across six Southeast Asian marketsPreferred investment option exercise, completed July 10, 2026, generated approximately $3.3 million in gross proceeds, further strengthening the Company's liquidity position and balance sheetNasdaq confirmed on July 13, 2026, that the Company regained compliance with the minimum bid price requirementLONDON, July 16, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX)
LONDON, July 10, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX) today closed its previously announced exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value $0.025 (the "Ordinary Shares") originally issued in October 2023 (as amended in December 2025) and in December 2025 having an original exercise price of $10.00 per share, at a reduced exercise price of $6.00 per share. The resale of the Ordinary Shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (Nos. 333-292241 and 333-275893). The gross p
DENVER, July 10, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- A wave of corporate announcements, from international distribution agreements and manufacturing leadership appointments to expanding government contracts and enterprise AI initiatives, several companies confirm strengthening revenue opportunities and long-term execution. Virax Expands into Southeast Asia Through Exclusive Fosun Diagnostics Partnership Virax Biolabs (NASDAQ:VRAX) announced a significant commercial milestone by signing an exclusive multi-country commercial supply agreement with Fosun Diagnostics covering Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia. The agreement allows immediate
H.C. Wainwright initiated coverage of Virax Biolabs Group Ltd. with a rating of Buy and set a new price target of $3.00
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
SC 13G/A - Virax Biolabs Group Ltd (0001885827) (Subject)
SC 13G - Virax Biolabs Group Ltd (0001885827) (Subject)
LONDON, July 29, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced the appointment of Iain Miller, PhD as an Independent Director to its Board of Directors, effective 29 July 2025. Dr. Miller succeeds Yair Erez, who is stepping down from the Board to focus on other professional endeavours. The Company thanks Mr Erez for his valuable service and contributions. Dr. Miller brings over 30 years of leadership expe
LONDON, Sept. 1, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the appointment of Dr. Nigel McCracken as the Company's Chief Operating Officer ("COO"). Dr. McCracken will succeed Mr. Cameron Shaw, who is moving to Virax's Advisory Board, and will lead the Company's various growth initiatives, including the Company's expected near-term research-use-only launch of ViraxImmune™. "We are excited to welcome Dr.
LONDON, Nov. 15, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales. "We are thrilled to welcome Richard to our team," said James Foster, Chairman of the Board and Chief Executive Officer of Virax Biolabs. "Richard brings almost 25 years of experience in successfully commercializing novel and disruptive technological products in the research, routine